Effect of PD-1/PD-L1 immune checkpoint inhibitor in squamous and nonsquamous non-small cell lung cancer:A systematic review and meta-analysis  

作　　者：Zhenjie Dai Jing Chen Yong Wang 

机构地区：[1]West China School of Medicine,West China Hospital,Sichuan University,Chengdu,Sichuan,China [2]Healthcare‐Associated Infection Control Center,Sichuan Provincial People's Hospital,University of Electronic Science and Technology of China,Chengdu,Sichuan,China [3]Division of Gastrointestinal Surgery,Department of General Surgery,West China Hospital,Sichuan University,Chengdu,Sichuan,China

出　　处：《Malignancy Spectrum》2024年第3期197-204,共8页肿瘤学全景(英文)

基　　金：supported by the Postdoctoral Foundation of West China Hospital, Sichuan University (2020HXBH102)

摘　　要：Background: The effects of programmed cell death protein 1/programmed cell death ligand 1(PD-1/PD-L1) immune checkpoint inhibitors(ICIs) in patients with squamous and nonsquamous non-small cell lung cancer(NSCLC) remain controversial. We conducted a meta-analysis to summarize the existing evidence on this topic.Methods: We searched Pub Med, Medline, and Embase for studies published before December 1, 2022, comparing PD-1/PD-L1 ICIs with docetaxel in squamous and nonsquamous NSCLC patients in any language. The different hazard ratio(HR) values for overall survival(OS)and progression-free survival(PFS) were calculated in this study.Results: A total of seven studies were identified. In a summary analysis of all studies, the HR values of OS in patients with nonsquamous and squamous NSCLC were 0.73, 95% confidence interval(CI): 0.67–0.79 and0.70, 95% CI: 0.62–0.79, respectively. In patients with PD-L1 expression levels of 1% or higher, the HR values of OS in nonsquamous and squamous NSCLC patients were 0.60, 95% CI: 0.49–0.74 and 0.72, 95% CI:0.54–0.96, respectively. The HR values of OS in nonsquamous and squamous NSCLC patients with PD-L1 expression levels of 5% or higher were 0.46, 95% CI: 0.35–0.59 and 0.55, 95% CI: 0.39–0.79, respectively. In nonsquamous and squamous NSCLC patients with PD-L1 expression levels of 10% or higher, the HR values of OS were 0.42, 95% CI: 0.32–0.54,and 0.53, 95% CI: 0.36–0.78, respectively.Conclusion: The meta-analysis demonstrated possible evidence that there was different efficacy of PD-1/PD-L1 ICIs on OS in squamous and nonsquamous NSCLC patients with different PD-L1 expression levels.Subgroup analysis showed that there was a greater OS benefit in patients with nonsquamous NSCLC.

关 键 词：PD‐1/PD‐L1 immune checkpoint inhibitor DOCETAXEL nonsquamous and squamous NSCLC meta‐analysis 

分 类 号：R734.2[医药卫生—肿瘤]